TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24298779

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neimadian (Extra) and Neiguan (PC 6)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 120
Study: 22187804

Group type: EXPERIMENTAL
Intervention: Oral amino acid supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No amino acid supplementation (Control)
Number of subjects: 50
Study: 18710603

Group type: EXPERIMENTAL
Intervention: Orange fruit (150 g)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Orange juice (300 g)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Juice (in extended dataset)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Age (as a variable)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Sex, BMI, contraceptive pill use (as variables)
Number of subjects: 129
Study: 16513458

Group type: EXPERIMENTAL
Intervention: Morning-dosed travoprost
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Evening-dosed travoprost
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both morning and evening dosings
Number of subjects: 33
Study: 12694428

Group type: EXPERIMENTAL
Intervention: CHX+CPC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+NaF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHX+ALC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study: 10513853

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 80
Study: 8951977

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2‐3 cups of coffee)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 1849730

Group type: EXPERIMENTAL
Intervention: Oral pyridostigmine 30 mg 8 hourly
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcuronium 1.5 mg
Number of subjects: 10
Study: 6755527

Group type: EXPERIMENTAL
Intervention: Immediate blood-pressure-lowering expectation group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed blood-pressure-lowering expectation group
Number of subjects: 0
Study: 30501915

Group type: EXPERIMENTAL
Intervention: Olive leaf tea (OLT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Green tea (GT)
Number of subjects: 31
Study: 30114553

Group type: EXPERIMENTAL
Intervention: Patients with sleep bruxism (SB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 50
Study: 27155740

Group type: EXPERIMENTAL
Intervention: Immediate androgen-deprivation therapy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Delayed androgen-deprivation therapy
Number of subjects: 293
Study: 24344104

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000/400 IU
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000/800 IU
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 22282548

Group type: EXPERIMENTAL
Intervention: Palovarotene 5 mg·day(‐1) for 1 year
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 20433277

Group type: EXPERIMENTAL
Intervention: Onyx
Number of subjects: 117

Group type: COMPARATOR
Intervention: N-butyl cyanoacrylate (NBCA)
Number of subjects: 117
Study: 18385594

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous naloxone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 97
Study: 15823678

Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Test (PVSAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 50
Study: 12460292

Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 20 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 30 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S-Caine peel applied for 60 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo applied for 20, 30, or 60 minutes
Number of subjects: 60
Study: 10503054

Group type: EXPERIMENTAL
Intervention: Postural adjustments in SCI individuals during a bimanual forward-reaching task.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Able-bodied controls during a bimanual forward-reaching task.
Number of subjects: 0
Study: 7477143

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 1938715

Group type: EXPERIMENTAL
Intervention: Liothyronine (triiodothyronine, T3) for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7091635

Group type: EXPERIMENTAL
Intervention: Atropine sulfate for premedication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-atropine group (no premedication)
Number of subjects: 28
Study: 29697455

Group type: EXPERIMENTAL
Intervention: Modified Blumgart mattress suture
Number of subjects: 224

Group type: COMPARATOR
Intervention: Interrupted suture
Number of subjects: 224
Study: 28528287

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (300mg b.i.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine combined with verapamil (80mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oxcarbazepine and MHD enantiomers
Number of subjects: 12
Study: 26683986

Group type: EXPERIMENTAL
Intervention: Lactotripeptides (10.2 mg/day)
Number of subjects: 40
Study: 23404211

Group type: EXPERIMENTAL
Intervention: EVE + EXE
Number of subjects: 143

Group type: COMPARATOR
Intervention: PBO + EXE
Number of subjects: 143
Study: 22479343

Group type: EXPERIMENTAL
Intervention: Knowledge, Attitude and Practice (KAP) intervention for fall prevention
Number of subjects: 3021
Study: 20047626

Group type: EXPERIMENTAL
Intervention: Omron HEM‐907XL
Number of subjects: 509
Study: 17530157

Group type: EXPERIMENTAL
Intervention: Standardised quantitative morphometry (SQM)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Quantitative morphometry (QM) using the Eastell‐Melton method
Number of subjects: 452

Group type: COMPARATOR
Intervention: Quantitative morphometry (QM) using GP-based reference data
Number of subjects: 452

Group type: COMPARATOR
Intervention: Quantitative morphometry (QM)
Number of subjects: 452
Study: 15629218

Group type: COMPARATOR
Intervention: NBD control subjects at 0 ms ISI
Number of subjects: 3

Group type: COMPARATOR
Intervention: NBD control subjects at 750 ms ISI
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LHD nonfluent aphasic patients at 0 ms ISI
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: LHD nonfluent aphasic patients at 750 ms ISI
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: RHD patients at 0 ms ISI
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: RHD patients at 750 ms ISI
Number of subjects: 3
Study: 11753137

Group type: EXPERIMENTAL
Intervention: Promising markers for diagnosis of interstitial cystitis; specific markers not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empiric treatment for interstitial cystitis; specific treatments not detailed.
Number of subjects: 0
Study: 10426620

Group type: EXPERIMENTAL
Intervention: Maternal serum betaHCG > or = 3.5 multiple of the median
Number of subjects: 192

Group type: COMPARATOR
Intervention: Maternal serum betaHCG < or = 2.0 multiple of the median
Number of subjects: 192
Study: 1574973

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methohexitone infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone combined with midazolam
Number of subjects: 40
Study: 3893488

Group type: EXPERIMENTAL
Intervention: Sotalol 1 mg/kg bolus intravenously plus 0.2 mg/kg intravenously over 12 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Digoxin 0.75 mg intravenously, then disopyramide 2 mg/kg intravenous bolus and 0.4 mg/kg/h intravenously for 10 hours
Number of subjects: 40
Study: 31308004

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 29031409

Group type: EXPERIMENTAL
Intervention: 15-20 mg DSP (Group 1A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham saline (Group 2A)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2.5-5 mg DSP (Group 1B)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 15-20 mg DSP (Group 2B)
Number of subjects: 2
Study: 26911204

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention focusing on healthy lifestyle, diet, exercise, and weight monitoring (4 sessions at 12‐15, 16‐18, 20‐24, and 37 weeks gestation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group received routine antenatal care
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 25547480

Group type: EXPERIMENTAL
Intervention: Informal hospice caregiving intervention
Number of subjects: 348
Study: 24124675

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 1985
Study: 20584994

Group type: EXPERIMENTAL
Intervention: Inhalation of 17.5% CO2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inhalation of 9% CO2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inhalation of 0% CO2
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Inhalation of CO2 (all dosages)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Interaction effect of genotype and CO2 dosage
Number of subjects: 96
Study: 18175148

Group type: EXPERIMENTAL
Intervention: IVMP (intravenous methylprednisolone pulse), 30 mg/kg/day for 3 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Additional IVIG, 2 g/kg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IVMP
Number of subjects: 15
Study: 16918262

Group type: EXPERIMENTAL
Intervention: Trastuzumab with chemotherapy followed by a year of trastuzumab
Number of subjects: 0
Study: 12612206

Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not supplemented with SP‐B
Number of subjects: 50

Group type: COMPARATOR
Intervention: Infants dying
Number of subjects: 50

Group type: COMPARATOR
Intervention: Infants in supplemental oxygen on day 28
Number of subjects: 50
Study: 10946985

Group type: EXPERIMENTAL
Intervention: 1-Day Acuvue
Number of subjects: 127

Group type: COMPARATOR
Intervention: Focus Dailies
Number of subjects: 127
Study: 9260009

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 8200169

Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus IVIG (500 mg/kg on days 1, 2, 3, and 8)
Number of subjects: 47
Study: 2455130

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Captopril (C)
Number of subjects: 16
Study: 30150756

Group type: EXPERIMENTAL
Intervention: Survival Metadata Analysis Responsive Tool (SMART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 0
Study: 27149595

Group type: EXPERIMENTAL
Intervention: EMG biofeedback-guided isometric exercises for 3 days a week for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional physical therapy program
Number of subjects: 36
Study: 24750839

Group type: EXPERIMENTAL
Intervention: Hormone treatment with dexamethasone 0.25‐0.3 mg/(kg·d) followed by oral prednisone tablets 0.5‐1 mg/(kg·d) for 7‐10 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine treatment with azithromycin and symptomatic therapies
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 108
Study: 23820151

Group type: COMPARATOR
Intervention: Pressure only
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pressure with fast cooling (‐4°C/min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pressure with slow cooling (‐0.33°C/min)
Number of subjects: 28
Study: 20801122

Group type: EXPERIMENTAL
Intervention: Linaclotide 75 μg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Linaclotide 150 μg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Linaclotide 300 μg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Linaclotide 600 μg
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Linaclotide (all doses)
Number of subjects: 420
Study: 19112204

Group type: COMPARATOR
Intervention: Clinical trial group (54 patients)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Outside clinical trial group (140 patients)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Patients receiving II line chemotherapy
Number of subjects: 194
Study: 16845121

Group type: EXPERIMENTAL
Intervention: Transvaginal approach
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 400
Study: 12671151

Group type: EXPERIMENTAL
Intervention: Thickened formula (carob bean gum)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonthickened formula
Number of subjects: 14
Study: 11155493

Group type: EXPERIMENTAL
Intervention: St. John's wort (e.g. Jarsin® coated tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antidepressants
Number of subjects: 0
Study: 8873114

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1468242

Group type: EXPERIMENTAL
Intervention: Audax ear drops
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cerumol ear drops
Number of subjects: 50
Study: 6365002

Group type: EXPERIMENTAL
Intervention: Ibuprofen 12 mg/kg by mouth, 1.5 hours prior to surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31060836

Group type: EXPERIMENTAL
Intervention: Fish oil (FOG) - 1.55 g of EPA + DHA per day for nine weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (PG) - Olive oil capsules
Number of subjects: 51
Study: 30592948

Group type: EXPERIMENTAL
Intervention: 37 °C normal saline (NS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 25 °C normal saline (NS)
Number of subjects: 24
Study: 26686755

Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² on week one followed by 250mg/m² on week 2-8
Number of subjects: 19

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19
Study: 24662443

Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB) using an Eliminate catheter (n = 71)
Number of subjects: 141

Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB) (n = 70)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PPCI with thrombectomy (TB)
Number of subjects: 141

Group type: COMPARATOR
Intervention: PPCI without thrombectomy (non-TB)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Post-procedure ISS volume
Number of subjects: 141
Study: 22031232

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Vinorelbine (GemVin)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin (GemCar)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Etoposide (GemEto)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Cisplatin (GemCis)
Number of subjects: 78
Study: 21030368

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 11849

Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 or 9 μg)
Number of subjects: 11849

Group type: EXPERIMENTAL
Intervention: Formoterol (18 μg)
Number of subjects: 11849

Group type: EXPERIMENTAL
Intervention: Formoterol (36 μg)
Number of subjects: 11849

Group type: EXPERIMENTAL
Intervention: Formoterol (variable dosing)
Number of subjects: 11849
Study: 17956916

Group type: COMPARATOR
Intervention: Advice and Exercise (A&E)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pulsed Shortwave Diathermy (PSWD)
Number of subjects: 350
Study: 15875535

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (conventional anti-diabetic treatment)
Number of subjects: 76
Study: 12195192

Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open colorectal resection
Number of subjects: 79
Study: 10195674

Group type: EXPERIMENTAL
Intervention: Pertussis vaccine
Number of subjects: 801
Study: 8658075

Group type: EXPERIMENTAL
Intervention: Powdered acidified full fat cow's milk fortified with 15 mg of iron as ferrous sulfate
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Powdered full fat cow's milk (non-fortified group)
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 1655
Study: 2209411

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (8 mg) daily for 18 days, then daily or alternate days from day 19-36
Number of subjects: 18
Study: 889372

Group type: EXPERIMENTAL
Intervention: Neomycin and erythromycin base
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 31067546

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation to achieve serum HCO3- levels of 24 ± 1 mmol/L
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rescue group with serum HCO3- levels of 20 ± 1 mmol/L
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Change of serum phosphate
Number of subjects: 35
Study: 28415988

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg in 2-12 months age group
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg in 3-6 years age group
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Mivacurium (various dosages)
Number of subjects: 640
Study: 26480545

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with motor imagery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional western medication and passive movement
Number of subjects: 62
Study: 23746749

Group type: EXPERIMENTAL
Intervention: Experimental material (test)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control material (DCL)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both test and control materials
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maxillary teeth
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: First molar teeth
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Supporting cusps
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lower dentures supported by implants
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Subjective wear assessment
Number of subjects: 47
Study: 21193975

Group type: EXPERIMENTAL
Intervention: BCG vaccine first
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hepatitis‐B vaccine first
Number of subjects: 76
Study: 19020904

Group type: EXPERIMENTAL
Intervention: Clinic-based physiotherapy with a behavioural approach
Number of subjects: 59

Group type: COMPARATOR
Intervention: Home-based training
Number of subjects: 59
Study: 16840383

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/d prednisone for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 24
Study: 12617264

Group type: EXPERIMENTAL
Intervention: Beta-interferon alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Beta-interferon combined with prednisone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study: 11783309

Group type: EXPERIMENTAL
Intervention: Rheum palmatum (RP) and captopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 9375818

Group type: EXPERIMENTAL
Intervention: Pulse oral calcitriol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous calcitriol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 1525793

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 20
Study: 3908009

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (single-dose preoperative)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study: 31027699

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 78

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low symptom burden (LSB)
Number of subjects: 78
Study: 27927602

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockade
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 27131642

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 25133963

Group type: EXPERIMENTAL
Intervention: etoricoxib 30 mg (qd)
Number of subjects: 239

Group type: COMPARATOR
Intervention: celecoxib 200 mg (qd)
Number of subjects: 239
Study: 22394170

Group type: EXPERIMENTAL
Intervention: 400 mg/day of EPA-DHA (n = 453)
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: 2 mg/day of ALA (n = 467)
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA (n = 458)
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Placebo (n = 472)
Number of subjects: 1850
Study: 19236730

Group type: EXPERIMENTAL
Intervention: BDNF rs7124442 TT genotype
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: BDNF rs7103411 TT genotype
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: BDNF rs6265 GG genotype
Number of subjects: 268
Study: 17344513

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d for 14 days)
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1074